Other Events ·
XORTX Therapeutics starts clinical and commercial manufacturing of XORLO for gout
XRTXXORTX Therapeutics Inc.
XORTX Therapeutics Inc. announced the initiation of clinical and commercial manufacturing for XORLO™ (oxypurinol), its proprietary formulation for treating gout, under the XRx-026 program. The company has begun contract production of GMP drug substance using a proprietary synthetic pathway and is working with a partner to manufacture commercial-scale tablets. This activity supports the planned two-part XRX-OXY-102 clinical study and builds validation data intended to support a future New Drug Application (NDA) filing for US FDA marketing approval. The company operates in the pharmaceutical industry, developing therapies for gout and kidney disease.